Literature DB >> 19169406

Primary effusion lymphoma diagnosed by pericardiocentesis.

Michael C Nemunaitis1, Jeffrey M Schussler, S Michelle Shiller, Louis M Sloan, Robert G Mennel.   

Abstract

Primary effusion lymphoma (PEL), formerly known as body cavity-based lymphoma, is a high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi's sarcoma and human herpesvirus 8 infection. It usually affects serous body cavities and results in recurrent lymphomatous effusions. PEL is often diagnosed in patients with HIV infection and carries a poor prognosis, with median survival near 6 months. We describe a patient who presented with symptomatic pericardial effusion, secondary to newly diagnosed PEL, and no prior history of HIV infection.

Entities:  

Year:  2009        PMID: 19169406      PMCID: PMC2626366          DOI: 10.1080/08998280.2009.11928479

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  29 in total

1.  The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.

Authors:  Hittu Matta; Preet M Chaudhary
Journal:  Cancer Biol Ther       Date:  2005-01-15       Impact factor: 4.742

2.  Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir.

Authors:  M Luppi; R Trovato; P Barozzi; D Vallisa; G Rossi; A Re; L Ravazzini; L Potenza; G Riva; M Morselli; G Longo; L Cavanna; R Roncaglia; G Torelli
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

3.  Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab.

Authors:  Soon Thye Lim; Nancy Rubin; Jonathan Said; Alexandra M Levine
Journal:  Ann Hematol       Date:  2005-03-31       Impact factor: 3.673

4.  Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.

Authors:  Emmanuelle Boulanger; Laurence Gérard; Jean Gabarre; Jean-Michel Molina; Christophe Rapp; Jean-François Abino; Jacques Cadranel; Sylvie Chevret; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2005-07-01       Impact factor: 44.544

5.  Complete remission of a primary effusion lymphoma with antiretroviral therapy.

Authors:  E Oksenhendler; J P Clauvel; S Jouveshomme; F Davi; G Mansour
Journal:  Am J Hematol       Date:  1998-03       Impact factor: 10.047

Review 6.  Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma.

Authors:  Carmen Manuela Klass; Margaret K Offermann
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

7.  Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.

Authors:  Shahab Uddin; Azhar R Hussain; Khaled A Al-Hussein; Pulicat S Manogaran; Amitha Wickrema; Marina I Gutierrez; Kishor G Bhatia
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

8.  Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen.

Authors:  G Gaidano; A Gloghini; V Gattei; M F Rossi; A M Cilia; C Godeas; M Degan; T Perin; V Canzonieri; D Aldinucci; G Saglio; A Carbone; A Pinto
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

Review 9.  Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8.

Authors:  G Dotti; R Fiocchi; T Motta; B Facchinetti; B Chiodini; G M Borleri; G Gavazzeni; T Barbui; A Rambaldi
Journal:  Leukemia       Date:  1999-05       Impact factor: 11.528

10.  Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA.

Authors:  Andrew Godfrey; John Anderson; Antigoni Papanastasiou; Yasu Takeuchi; Chris Boshoff
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.